Skip to main content

Market Overview

Biomarin Pharmaceutical Q4 Earnings Outlook


Don't be caught off-guard: Biomarin Pharmaceutical (NASDAQ: BMRN) releases its next round of earnings Thursday.

Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.

Earnings and Revenue

Biomarin Pharmaceutical EPS is expected to be at a loss of 24 cents, according to sell-side analysts. Sales will likely be near $357.49 million.

In the same quarter last year, Biomarin Pharmaceutical posted a loss of 53 cents per share on sales of $300 million. If the company were to match the consensus estimate, earnings would be down 54.72 percent. Revenue would be up 19.13 percent from the year-ago period.

Here's how the company's EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.1 -0.21 -0.29 -0.38
EPS Actual -0.07 -0.21 -0.09 -0.53


Stock Performance

Over the last 52-week period, shares are down 6.7 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts have been rating Biomarin Pharmaceutical stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Biomarin Pharmaceutical's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here:


Related Articles (BMRN)

View Comments and Join the Discussion!

Posted-In: Earnings News Previews Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at